Soticlestat

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Soticlestat 是一种有效的、选择性的、口服活性的胆固醇 24-羟化酶 (CYP46A1) 抑制剂。

Soticlestat is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. It has the potential for epilepsy syndromes research.

——

Animal Model:Amyloid precursor protein and presenilin 1 (APP/PS1-Tg) mice (7-week-old)Dosage:10 mg/kg Administration:Oral administration; once daily; for 1 days, 3 days and 7 days Result:Lowered brain 24S-hydroxycholesterol in a dose-dependent manner and substantially reduced premature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 50%.

OV935 | TAK-935

Metabolic Enzyme/Protease

P450

CYP46A1

——

——

1429505-03-2

373.46

C23H23N3O2

>98% (HPLC)

DMSO:100 mg/mL (267.77 mM; Need ultrasonic)

C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4

——

(-20℃)

With Ice Pack

≥ 2 years